Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP7 | P09237 | 1/20 | 0.55 |
| ▸ | MMP14 | P50281 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19066539 | 0.98 | ALDH1A1 (0.63) | ALDH1A1NPC1HSD11B1POLBMMP2 | |
| SCHEMBL27584145 | 0.82 | ALDH1A1 (0.55) | ALDH1A1NPC1HSD11B1POLBKMT2A | |
| SCHEMBL270706 | 0.82 | MMP2 (0.77) | ALDH1A1HSD11B1POLBMMP2MMP7 | |
| SCHEMBL1017207 | 0.82 | ALDH1A1 (0.65) | ALDH1A1NPC1MMP2MMP7MMP14 | |
| Guanidine SCHEMBL2279843 | 0.82 | MMP2 (0.65) | HSD11B1POLBMMP2MMP7MMP14 | |
| SCHEMBL3479371 | 0.81 | ALDH1A1 (0.69) | ALDH1A1NPC1POLBMMP2MMP7 | |
| SCHEMBL5467897 | 0.81 | HSD11B1 (0.53) | ALDH1A1NPC1HSD11B1POLBMMP2 | |
| SCHEMBL9136704 | 0.81 | HSD11B1 (0.53) | ALDH1A1NPC1HSD11B1POLBMMP2 | |
| SCHEMBL7855586 | 0.80 | HSD11B1 (0.53) | ALDH1A1HSD11B1POLBMMP2MMP7 | |
| SCHEMBL23863544 | 0.80 | HSD11B1 (0.62) | ALDH1A1NPC1HSD11B1POLBMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563055-A | Aminopyrazine compound or salt, isomer, preparation method and application thereof | 成都苑东生物制药股份有限公司 | 2019-04-02 | — | — | CN | claimed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| EP-1971600-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2008-09-24 | — | — | EP | claimed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | claimed |
| WO-2005047271-A1 | PROCESS FOR THE SYNTHESIS OF 6-CHLORO-2,5-DICARBONAMIDOPHENOLS AND BENZOXAZOLE DERIVATIVES AS INTERMEDIATES | EASTMAN KODAK COMPANY (US) | 2005-05-26 | — | — | WO | claimed |
| US-20050101784-A1 | Compounds and synthesis process | EASTMAN KODAK COMPANY | 2005-05-12 | — | — | US | claimed |
| US-6201125-B1 | REDUCING A 2-ALKYL-6-NITRO-BENZOXAZOLE TO FORM A 2-ALKYL-6-AMINO-BENZOXAZOLE IN WHICH THE 2-ALKYL GROUP IS UNBRANCHED AT THE ALPHA CARBON; COUPLERS | EASTMAN KODAK COMPANY | 2001-03-13 | — | — | US | claimed |
| EP-0415631-B1 | Electrodeposition of palladium films | AMERICAN TELEPHONE & TELEGRAPH (US) | 1994-05-18 | — | — | EP | claimed |
| EP-0415631-A1 | Electrodeposition of palladium films | AT&T Corp. (US) | 1991-03-06 | — | — | EP | claimed |
| US-4911799-A | Electrodeposition of palladium films | AT&T BELL LABORATORIES (US) | 1990-03-27 | — | — | US | claimed |
| CN-116574099-A | Phosphodiesterase inhibitors and uses | 南京征祥医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-3710592-B1 | MICROBIOLOGICAL PROCESS FOR THE PREPARATION OF AMIDES | COLUMBIA S R L (IT) | 2022-08-31 | — | — | EP | disclosed |
| US-11261468-B2 | Microbiological process for the preparation of amides | COLUMBIA SRL (IT) | 2022-03-01 | — | — | US | disclosed |
| US-4347380-A | N-Acylsulfonamide herbicidal antidotes | STAUFFER CHEMICAL COMPANY (US) | 1982-08-31 | — | — | US | disclosed |
| US-4116965-A | STYRYL DYESTUFFS CONTAINING CERTAIN AMINO, CYANOPYRIDINE MOIETIES | CIBA-GEIGY CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4115566-A | 7α Ureido cephem-4-carboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
| US-3954802-A | Substituted-ureido derivatives of penam 3-carboxylic acid and cephem 4-carboxylic acid | CIBA-GEIGY CORPORATION (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101784-A1 | Compounds and synthesis process | CYP2B6, DDC, DAO | ALDH1A1 2260/4885NPC1 3553/4885HSD11B1 2978/4885 |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | ALDH1A1 706/4885NPC1 2242/4885HSD11B1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.